The predicted share price (Closing Price) for Bafna Pharmaceuticals Ltd for tomorrow (2026-04-09) is ₹112.71 which is 3.40% higher than today’s share price of ₹109.00
Bafna Pharmaceuticals Ltd – Investor Insights
Valuation StatusiCompares the stock's intrinsic value (calculated from fundamentals like earnings, book value, and growth) with the current market price (CMP). Undervalued = potential buying opportunity. Overvalued = the market may be pricing in too much optimism.
Overvalued
Intrinsic ₹53.57 vs CMP ₹109.00 (-50.9%)
Market RegimeiShows whether the stock is in an uptrend (bullish) or downtrend (bearish) based on its Exponential Moving Average (EMA). When price is above EMA → bullish momentum. Below EMA → bearish pressure. This affects how our model adjusts volatility and predictions.
▼ Bearish
Price/EMA: 0.896 · EMA(252): ₹121.67
VolatilityiMeasures how much the stock price swings. Low (<25%) = stable, predictable price movement. Moderate (25-40%) = normal for most stocks. High (>40%) = large daily swings, higher risk. The "recent trend" shows if volatility is currently increasing or decreasing compared to its historical average.
57% annualized
Risk: High · Recent trend: Rising (recent > historical)
Trend MemoryiThe Hurst Exponent measures whether price movements tend to continue (trending) or reverse (mean-reverting). Above 0.55 = momentum persists, recent trends likely to continue. Below 0.45 = price tends to snap back after big moves. Around 0.5 = random walk, past moves don't predict future direction.
Random walk
Hurst exponent: 0.527
Projected CAGRiCompound Annual Growth Rate — the average yearly return if the stock reaches our projected price target. 5Y and 10Y show different time horizons. Higher CAGR = faster expected growth. Negative CAGR = the model projects the stock may decline from current levels.
+2.7%5Y+1.5%10Y
Historical drift: +11.9% annualized
Risk-Reward RatioiCompares your potential upside (to intrinsic value) against potential downside (to fundamental floor). Above 2x = favorable risk-reward, potential gain is at least double the potential loss. Below 1x = unfavorable, you risk losing more than you could gain. A negative value means the stock is already above intrinsic value.
-0.52x
Upside -50.9% vs downside 97.2% · Unfavourable
Margin of SafetyiA concept from value investing (Benjamin Graham). It measures how much cheaper the stock is compared to its intrinsic value. Positive margin = you're buying below fair value (safety cushion). Negative margin = you're paying more than the stock is fundamentally worth. Most value investors look for at least 15-25% margin of safety.
-103.5%
No margin
Model ConfidenceiShows how reliable our predictions are for this stock. Based on the model's average prediction error over the last 90 days. Low error = high confidence. Also shows data coverage — more data points over longer periods produce more reliable projections. The model self-learns by adjusting parameters every 7 days.
Low
Avg error: 8.61% · 584 data points over 594 days
Fundamental FlooriThe lowest price the stock is expected to reach under normal market conditions, based on book value and financial strength (ROE, ROCE, debt ratios). A very low floor relative to CMP means the company has limited tangible asset backing at current prices. In extreme market crashes, prices can temporarily breach this level.
₹3.02
(97.2% below CMP)
What this means: Bafna Pharmaceuticals Ltd appears overvalued by 50.9% relative to intrinsic value. The stock is currently in a bearish regime (price below EMA). Volatility is high (57% annualized), implying wider price swings and higher risk.
Will Bafna Pharmaceuticals Ltd share price increase tomorrow?
Bafna Pharmaceuticals Ltd share price is expected to increase to ₹112.71 on 2026-04-09, which is 3.40% higher than today's price of ₹109.00. This prediction is based on our AI-powered GFBM model.
What is the intrinsic value of Bafna Pharmaceuticals Ltd?
Bafna Pharmaceuticals Ltd intrinsic value is ₹53.57, which is 50.85% below the current price of ₹109.00. This suggests the stock is currently overvalued.
What is the share price target of Bafna Pharmaceuticals Ltd in 2027?
Bafna Pharmaceuticals Ltd share price target for 2027 is projected to reach ₹108.81 by year-end (range: ₹107.52 to ₹109.73), representing a -0.17% decrease from the current price of ₹109.00.
What is the share price target of Bafna Pharmaceuticals Ltd in 2028?
Bafna Pharmaceuticals Ltd share price target for 2028 is projected to reach ₹110.70 by year-end (range: ₹108.31 to ₹113.87), representing a 1.56% increase from the current price of ₹109.00.
What is the share price target of Bafna Pharmaceuticals Ltd in 2029?
Bafna Pharmaceuticals Ltd share price target for 2029 is projected to reach ₹115.96 by year-end (range: ₹111.03 to ₹116.24), representing a 6.39% increase from the current price of ₹109.00.
How are Bafna Pharmaceuticals Ltd share price targets calculated?
The share price targets are calculated using Geometric Fractional Brownian Motion (GFBM), combining historical price data, volatility analysis, Hurst exponent for long-term memory effects, and Exponential Moving Averages (EMA) for trend analysis and regime detection.
Bafna Pharmaceuticals Ltd Share Price Prediction – How We Calculate the Targets
We calculate the share price targets for Bafna Pharmaceuticals Ltd using a combined approach of Geometric Fractional Brownian Motion (GFBM) and the Exponential Moving Average (EMA) for trend analysis. This hybrid model incorporates historical price data, memory effects through the Hurst exponent, and dynamic regime shifts based on the stock's trends. Below are the detailed steps of how these projections are calculated.
Step 1: Calculate the Log Returns
The log returns measure the relative change in stock prices over time. It is calculated as follows:
The Hurst exponent measures the "memory" or persistence of the stock price movement. It is calculated as follows:
\[ H = \frac{\log(R/S)}{\log(n)} \]
Step 6: Project Future Share Prices Using GFBM and EMA
The future price of the stock is projected using a combined model of Geometric Fractional Brownian Motion (GFBM) and Exponential Moving Average (EMA) for trend-based regime switching.
Step 7: Predicting Tomorrow's Stock Price for Bafna Pharmaceuticals Ltd
The predicted price for tomorrow is derived using the Geometric Brownian Motion (GBM) formula with drift, volatility, and a random factor to simulate market movements.
Step 8: Projected Share Prices for the Next 10 Years
The projected share prices for the next 10 years are calculated using the combined GFBM and EMA model, taking into account historical growth, volatility, and market trends.
Conclusion
Our hybrid approach provides a realistic projection of share prices for Bafna Pharmaceuticals Ltd over the next 10 years by considering historical performance, volatility, market memory, and current trends.
The projected stock prices are provided for informational purposes only and do not constitute investment advice or recommendations. Past performance of securities is not indicative of future results. Getaka Financial Technology is not responsible for any investment decisions made on the basis of this information. Investors are advised to seek independent financial advice from a SEBI-registered investment advisor before making any investment decisions. Investments in the securities market are subject to market risks. Please read all associated offer documents and terms carefully before investing.
